Acute Myeloid Leukemia (Aml)

(Acute myeloid leukemia, acute myeloid leukemia)

In acute myeloid leukemia (AML), the malignant transformation and uncontrolled proliferation to an abnormally differentiated, durable myeloid progenitor cell to an increased number of immature cell precursors in the blood and a displacement of the normal bone marrow by malignant cells. The clinical symptoms are fatigue, paleness, easy bruising and bleeding, and fever and infection. Only about 5% of patients show symptoms of extramedullary leukemic infiltration (often skin infiltration). The diagnosis is made based on peripheral blood smears and bone marrow examination. The treatment consists in an induction chemotherapy, is to be achieved by the remission, and a post-remission chemotherapy (with or without stem cell transplantation) to prevent recurrence.

For an overview of acute leukemia, Overview: Acute leukemia.

In acute myeloid leukemia (AML), the malignant transformation and uncontrolled proliferation to an abnormally differentiated, durable myeloid progenitor cell to an increased number of immature cell precursors in the blood and a displacement of the normal bone marrow by malignant cells. The clinical symptoms are fatigue, paleness, easy bruising and bleeding, and fever and infection. Only about 5% of patients show symptoms of extramedullary leukemic infiltration (often skin infiltration). The diagnosis is made based on peripheral blood smears and bone marrow examination. The treatment consists in an induction chemotherapy, is to be achieved by the remission, and a post-remission chemotherapy (with or without stem cell transplantation) to prevent recurrence. For an overview of acute leukemia, Overview: Acute leukemia. AML is the most common acute leukemia in adults. Its incidence increases with age; the median age of onset is about 50 years. AML can occur as Sekundärneoplasie after prior chemotherapy or radiation therapy for another tumor disease. Secondary AML can be treated solely with chemotherapy difficult. By morphology, immunophenotyping and cytochemistry different subtypes of AML can be distinguished. A total of five different subtypes are described according to the predominant cell type, as a Myelozytär Myelomonozytär monocytic erythroid Megakaryozytär The acute promyelocytic leukemia (APL) is a subtype of particularly significant since it accounts for 10-15% of all AML cases and often younger patients (median age 31 years) and ethnic subgroups (Latin American) concerns. Often the first symptom is a clinical coagulopathy. Acute promyelocytic leukemia with permission of the publisher. From Chang K., Forman S. In Atlas of Clinical Hematology. Edited by J. O. Armitage. Philadelphia, Current Medicine, 2004. var model = {thumbnailUrl: ‘/-/media/manual/professional/images/acute_promyelocytic_leukemia_high_de.jpg?la=de&thn=0&mw=350’ imageUrl: ‘/ – / media / manual / professional / images / acute_promyelocytic_leukemia_high_de.jpg lang = en & thn = 0 ‘, title:’? Acute promyelocytic leukemia ‘description:’ u003Ca id = “v37895174 ” class = “”anchor “” u003e u003c / a u003e u003cdiv class = “”para “” u003e u003cp u003eAkute promyelocytic leukemia is usually the easiest to diagnose acute myeloid leukemia

Health Life Media Team

Leave a Reply